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Mutations in the gene coding for the renal tight junction protein claudin 16 cause familial hypomagnesemia with
hypercalciuria and nephrocalcinosis, an autosomal recessive disorder of renal Ca2+ and Mg2+ handling that pro-
gressively leads to chronic renal failure, with nephrolithiasis having been reported in heterozygous carriers. Screening
a cohort of 11 families with idiopathic hypercalciuria identified a novel homozygous mutation in the claudin 16
gene in two families. In contrast to classical symptoms of familial hypomagnesemia with hypercalciuria and
nephrocalcinosis, the patients displayed serious but self-limiting childhood hypercalciuria with preserved glomerular
filtration rate. The mutation results in inactivation of a PDZ-domain binding motif, thereby disabling the association
of the tight junction scaffolding protein ZO-1 with claudin 16. In contrast to wild-type claudin 16, the mutant no
longer localizes to tight junctions in kidney epithelial cells but instead accumulates in lysosomes. Thus, mutations
at different intragenic sites in the claudin 16 gene may lead to particular clinical phenotypes with a distinct prognosis.
Mutations in claudin 16 that affect interaction with ZO-1 lead to lysosomal mistargeting, providing—for the first
time, to our knowledge—insight into the molecular mechanism of a disease-associated mutation in the claudin 16
gene.
Introduction
Hypercalciuria (HC) is a common cause of nonglome-
rular hematuria, nocturnal enuresis, and frequency dys-
uria in children (Stapleton et al. 1984; Alon et al. 1990).
In children and adults, it is one of the major determinants
of calcium-related kidney-stone diseases and nephrocal-
cinosis (NC) (Asplin 1996). However, HC represents a
common symptom of various underlying disorders,
meaning that the etiology of HC is heterogeneous. One
such disorder, familial hypomagnesemia with HC and
NC (FHHNC [MIM 248250]), a progressive disorder
of renal Ca2 and Mg2 wasting leading to chronic
renal failure, is caused by mutations in the claudin 16
(CLDN16) gene (also known as “paracellin-1” gene)
(Simon et al. 1999; Weber et al. 2001b). CLDN16 is a
member of a family of membrane-bound proteins that
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constitute the intercellular tight-junction (TJ) barrier in
various epithelia (Morita et al. 1999). Claudins span the
lipid bilayer four times, with their two luminal loops
mediating cell-cell adhesion via homo- or heterotypic
interaction with claudins on a neighboring cell (Tsukita
et al. 2001). In addition, claudins form paracellular ion
channels, the characteristic permeability of an epithe-
lium thought to arise from the particular claudin mol-
ecules expressed (Heiskala et al. 2001). Cytosolic scaffold
proteins of the ZO family (i.e., ZO-1, ZO-2, and ZO-3)
link TJ transmembrane proteins to the actin cytoskeleton
and recruit signaling molecules to regions of cell-cell con-
tact (Gonzalez-Mariscal et al. 2000). CLDN16 is exclu-
sively expressed in the thick ascending part of Henle’s
loop, where it is believed to form paracellular channels
that allow reabsorption of Ca2 and Mg2 and are ba-
sically driven by an electrochemical gradient (Simon et
al. 1999). Consequently, patients with FHHNC expe-
rience severe renal Ca2 and Mg2 wasting, which leads
to chronic renal failure.
Because a recent study of patients with FHHNC
suggested that heterozygously affected family mem-
bers might be at an increased risk of developing renal-
stone disease, we investigated a cohort of families with
HC for mutations in the CLDN16 gene (Weber et al.
2001b). It was surprising that we identified a novel ho-
mozygous mutation in the CLDN16 gene in the affected
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members of two families in this cohort. In contrast to
the clinical phenotype thus far reported to be associated
with mutations in the CLDN16 gene, the phenotype of
this mutation is characterized by serious but self-limit-
ing symptoms of HC during childhood with conserved
kidney function. Biochemical and cell biological char-
acterization of the wild-type and mutant CLDN16 pro-
vide a molecular mechanism for this rare phenotype.
These findings indicate that the clinical appearance and
long-term prognosis of mutations in CLDN16 is deter-
mined by the location of the mutation within the gene.
Methods
Mutation Analysis of the CLDN16 Gene
Genomic DNA of available members of 11 families
with HC was isolated from peripheral leukocytes, and
all exons of the CLDN16 gene were amplified by using
oligonucleotides that anneal to noncoding (intronic) sites
∼30 bp from the intron-exon boundaries (GenBank ac-
cession number NT005883) as described elsewhere (Meij
et al. 2003). This family cohort also included nine fam-
ilies from an earlier study (Muller et al. 2002a). PCR
products were purified, sequenced (Perkin Elmer), and
compared with the published human CLDN16 sequence
(GenBank accession number AF152101) (Simon et al.
1999). Consent for the studies was obtained from pa-
tients or a parent, in accordance with the local guidelines
at each participating institution. DNA for sequencing
the CLDN16 exons on control chromosomes was ob-
tained from blood donated by healthy volunteers of Eu-
ropean descent.
Antibodies and Plasmids
The antibodies used were rabbit anti-human ZO-1
(Zymed), rat monoclonal anti-HA (Roche), mouse
monoclonal anti–dog-lamp-2 (AC17) (Nabi et al. 1991),
and mouse monoclonal anti–rat GM130 (Nakamura et
al. 1997). HRP-labeled secondary antibodies were from
Jackson Laboratories and Pierce; fluorescently labeled
(Alexa 488 and 594) secondary antibodies were from
Molecular Probes. The full-length human CLDN16
cDNA was obtained by PCR from a kidney cDNA li-
brary (Clontech), using suitable primers covering the 5′
and 3′ coding region of the cDNA. The primers were
designed to introduce a 5′ EcoRI site, an N-terminal HA-
epitope tag, and a 3′ XbaI restriction site. The epitope
tag was fused in frame after the second translation-
initiation site, which, according to sequence comparison
and mutation analysis, is used in vivo (Ohba et al. 2000;
Weber et al. 2001a, 2001b). A suitable 3′ PCR primer
was used to introduce the T233R mutation; two over-
lapping primers were used to construct the G128A mu-
tant. All cDNA constructs were verified by sequencing
and subcloned into pcDNA3 (Invitrogen) for expression
in Madin-Darby canine kidney (MDCK) cells. Con-
structs coding for the three PDZ domains of ZO-1, ZO-
2, and ZO-3 in pcDNA3 were used for in vitro tran-
scription and translation. Sequences of primers are
available upon request.
Culture and Transfection of MDCK Cells
MDCK strain II cells were cultured and transfected as
described elsewhere (Reichert et al. 2000). Clones stably
expressing wild-type or mutant CLDN16 were selected
for the presence of G418 and were screened for expres-
sion by immunofluorescence or western blot analysis,
after induction with 5 mM butyrate for 12 h (Ho¨ning
and Hunziker 1995). Polarized cell monolayers were ob-
tained by growing cells on 0.4 mm Transwell polycar-
bonate filters (Costar).
Pull-Down Experiments
Peptides corresponding to the 11 C-terminal amino
acids of wild-type or T233R mutant CLDN16 were cus-
tom synthesized and coupled to Dynabeads (Dynal) by
Biogenes. Labeled PDZ domains of ZO-1, ZO-2, or ZO-
3 were generated by in vitro transcription and transla-
tion (Quick Coupled T7 TNT; Promega) in the presence
of radioactive methionine. Between 5 and 10 ml of the
in vitro transcription and translation reaction were in-
cubated with peptide-coupled Dynabeads (2–10 mg pep-
tide) for 2 h at 4C in binding buffer (25 mM Tris [pH
7.5], 50 mM NaCl, and 0.1% Tween-20; or Triton X-
100, 20 mM MgCl2, and 1 mM DTT). Beads were then
rinsed with washing buffer (25 mM Tris [pH 7.5], 150
mM NaCl, and 0.1% Tween-20; or Triton X-100, 20
mM MgCl2, and 1 mM DTT) and were resuspended in
SDS sample buffer. Bound PDZ domains were analyzed
by SDS-PAGE and autoradiography. For competition ex-
periments, in vitro translated PDZ domains were prein-
cubated with 100 mM uncoupled wild-type or T233R
peptide before addition to the beads.
Coimmunoprecipitations
Control cells or MDCK cells stably expressing HA-
tagged wild-type or mutant CLDN16 were washed with
PBS and lysed on ice in lysis buffer (0.5% Triton X-100
in PBS supplemented with a protease inhibitor cocktail).
The postnuclear supernatant was precleared and im-
munoprecipitated with anti–ZO-1 (Zymed) or anti-HA
(Roche) antibodies and protein G sepharose (Pharma-
cia). Immunoprecipitates were washed with lysis buffer,
fractionated by SDS-PAGE (10% acrylamide), blotted
onto polyinylidene difluoride membranes, and probed
with antibodies against HA or ZO-1, respectively, fol-
lowed by incubation with suitable HRP-labeled second-
ary antibodies (Jackson Laboratories and Pierce) and
chemiluminescence detection (Pierce).
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Figure 1 Clinical and molecular data regarding patients from two
families with infantile familial HC with NC. a, Pedigrees of patient
families. Blackened symbols indicate affected individuals; unblackened
symbols indicate nonaffected individuals; squares indicate males; circles
indicate females. Family B is consanguineous (see text for details). b,
Sequencing data for the region in the CLDN16 gene carrying the T233R
mutation. Homozygous (/) amino acid exchange (TrR) was detected
in affected patients A3, A4, A6, and B6; heterozygous (/) mutations
were detected in the nonaffected members A1, A2, A7, B1, and B2.
Individuals B3, B4, and B5 were not available for analysis (“n.d.”).
Sequences in the chromatogram read from 3′ to 5′, and the mutation is
indicated with an asterisk (*). The coding and corresponding amino acid
sequences are provided above the chromatogram. c, Urinary Ca2 ex-
cretion decreases to levels within the normal range when patients reach
adolescence. Ca2 excretion was measure in affected members of families
A and B during follow-up.
Immunofluorescence Microscopy
MDCK cells grown on glass cover slips or Transwell
filters (Costar) were fixed with 3.7% paraformaldehyde
for 30 min and were permeabilized with 0.2% Triton
X-100 in PBS. After blocking with 10% goat serum
(GibcoBRL), cells were incubated with different primary
antibodies (5mg/ml) followed by suitable fluorescent sec-
ondary antibodies (1:1,000). Images were acquired us-
ing a confocal laser scanning microscope (BioRad) and
IMARIS software (Bitplane), essentially as described by
Kausalya et al. (2001).
Results
Identification of a Novel Mutation in the CLDN16
Gene
Screening for mutation in the CLDN16 gene was per-
formed in 27 individuals from a cohort of 11 families
with HC (Weber et al. 2001b); 18 members of 9 families
(in each family, one affected and one nonaffected mem-
ber were investigated) did not show a mutation in any
of the sequenced alleles. However, in two families—one
of Scandinavian (A) and the other of Spanish (B) origin—
mutation screening revealed a novel single homozygous
substitution of a cytosine for a guanine at position 697
of the ORF in patients A3, A4, A6, and B6 (fig. 1a and
1b). Individuals A1, A2, and A7, as well as B1 and B2,
were heterozygous for the mutation, whereas A5, B3,
B4, and B5 were not eligible for genotyping. At the pro-
tein level, the mutation results in the substitution of a
conserved C-terminal threonine, at position 233, for an
arginine (T233R; fig. 2). Sequencing the corresponding
exon of the CLDN16 gene of 111 unaffected individ-
uals, together with previous analysis of 160 control chro-
mosomes (Simon et al. 1999), did not reveal polymor-
phisms or allelic variations.
Clinical Characterization of Patients Carrying the
T233R Mutation
The second youngest child of family A (A6; fig. 1a)
was admitted to the clinic for nocturnal enuresis. Di-
agnostic work-up revealed marked HC (10.1 mg/kg
body weight per 24 h; fig. 1c) and renal medullary NC.
Because the mother reported nocturnal enuresis and uri-
nary tract infections in two of the other siblings, bio-
chemical and ultrasound investigations were performed
for all children, revealing HC and NC in patients A3
and A4, but the other children (A5 and A7) were un-
remarkable. During the 6-year follow-up period, urinary
Ca2 excretion decreased in each consecutive year in the
affected children (fig. 1c), and, despite their age differ-
ences, there was a clear linear decrease over time in all
patients. Although NC was still detectable on renal ul-
trasound examination, the oldest affected sister already
displayed normal values for Ca2 excretion at the time
of the last examination (fig. 1c and 1d). Glomerular
filtration rate remained normal in all children affected
(112–122 ml/min/1.73 m2), with no evidence of a further
progression of medullary NC (data not shown, ultra-
sound images available on request). In all affected mem-
bers, Mg2 levels were within the low normal ranges
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Figure 2 Predicted topology of CLDN16 and location of the different mutations reported. Shown is the amino acid sequence from the
second translation-initiation site, which is used in vivo (Ohba et al. 2000; Weber et al. 2001a, 2001b). Mutated amino acids thus far reported
in the literature that are associated with classical FHHNC are shown (Simon et al. 1999; Weber et al. 2000; Weber et al. 2001b) (yellow), with
the G128A mutation characterized in this study highlighted (blue). The C-terminal PDZ binding motif (red) and the novel T233R mutation
encountered in the patients of families A and B (blue) are also shown. Tyrosine residues in the C-terminal cytosolic domain of CLDN16 that
may be part of endocytosis and/or lysosomal sorting signals are indicated (gray).
(1.8, 1.7, and 1.6 mg/dl), although they were consistently
lower than in the nonaffected members (2.2 and 2.1 mg/
dl), and urinary Mg2 excretion was slightly elevated
in the patients (0.13–.02 mmol/kg body weight per
24 h vs. 0.03–0.07 mmol/kg body weight per 24 h).
1,25(OH)2D3 (42–59 pg/ml), as well as intact parathy-
roid hormone (iPTH) levels, were within the normal
ranges in all cases as were urinary sodium and potassium
levels and their fractional excretion (patients A3, A4,
and A6). During a 6-wk Ca2 restriction test on the
patients of family A, urinary Ca2 remained constant
and 1,25(OH)2D3 and iPTH levels increased. This effect
was reversible when the patients were returned to a nor-
mal Ca2-containing diet (1000 mg/d). In all affected
individuals, a daily dose of 20 mg intranasally admin-
istered desmopressin resolved nocturnal enuresis with-
out affecting urinary Ca2 excretion.
The parents of family B (B1 and B2; fig. 1b) were
second-degree relatives. The patient (B6) had three
healthy brothers (B3–B5) and was first admitted to the
hospital at the age of 5 years for recurring urinary tract
infections and nephrolithiasis. He showed marked HC
(12.9 mg/kg body weight per 24 h). Renal ultrasound
showed medullary NC. Elevated levels of plasma renin
and aldosterone and of urinary prostaglandin E2 were
also observed. During the years of follow-up, the patient
was admitted several times for nephrolithiasis. As for
classical FHNNC, administration of hydrochlorothia-
zide did not reduce the amount of urinary Ca2 excre-
tion, indicating that the anticalciuric capabilities of thia-
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Figure 3 Binding of wild-type and mutant CLDN16 to ZO-1. a, Wild-type CLDN16, but not the T233R mutant, binds to the ZO-1 but
not the ZO-2 and ZO-3 PDZ domains. In vitro translated and radioactively labeled ZO-1, ZO-2, or ZO-3 PDZ domains were incubated with
peptides corresponding to the C-terminus of wild-type or T233R mutant CLDN16 coupled to beads. Protein bound to the beads (“Pull-Down”)
was analyzed by SDS-PAGE and autoradiography, and an aliquot (5%) of the in vitro translated material was directly analyzed to confirm that
similar amounts of the in vitro translated proteins were added to the binding reaction (“Input”). b, Preincubation with wild-type, but not T233R
mutant, peptides competes with ZO-1 PDZ binding to beads. In vitro translated and radioactively labeled ZO-1 PDZ domains were pre-
incubated with soluble wild-type or mutant CLDN16 peptides prior to the incubation with the peptide-coupled beads. c, Wild-type CLDN16,
but not the T233R mutant, coprecipitates with ZO-1. Control cells (MDCK) or cells stably expressing wild-type (CLDN16) or mutant (T233R)
CLDN16 were lysed, and equal amounts of total protein were used to immunoprecipitate CLDN16. Precipitates were blotted with anti–ZO-
1 antibody to detect ZO-1 bound to CLDN16. In the reverse experiment, wild-type, but not mutant CLDN16, which is also associated with
anti–ZO-1, precipitates (data not shown). Aliquots of the cell lysate were blotted directly to confirm that the cells expressed similar amounts
of ZO-1, as well as wild-type and mutant CLDN16 (“Input”). WT p wild type.
zides are surpassed by the unreabsorbed Ca2 load.
Glomerular filtration rates always remained within nor-
mal range (last value 102.4 ml/min/1.73 m2). During
follow-up, urinary Ca2 excretion decreased (8.5 mg/
kg body weight per 24 h at 11 years of age) and was
within normal range at the last visit (at age 20 years)
(fig. 1c). Asymptomatic hypomagnesemia (1.4 mg/dl)
was encountered once at the age of 17 years. The most
recent ultrasound of the kidneys showed that NC did
not progress.
CLDN16, but Not the T233R Mutant, Binds to ZO-1
T233 is part of the C-terminal threonine-arginine-val-
ine (TRV) sequence that resembles a putative type 1
PDZ-binding motif (Saras and Heldin 1996; Hung and
Sheng 2002), and some claudins have been reported to
interact with PDZ-domain proteins, in particular the TJ
scaffold proteins ZO-1, ZO-2, and ZO-3 (Itoh et al.
1999; Gonzalez-Mariscal et al. 2000). We therefore de-
termined whether CLDN16 interacts with ZO proteins
and localizes to TJ and whether the interaction or lo-
calization is affected by the T233R mutation.
Immobilized peptides corresponding to the C-terminal
11 amino acids of wild-type CLDN16 bound in vitro
translated PDZ domains of ZO-1, showing that the TRV
sequence codes for a functional PDZ-binding motif. No
specific interaction with the PDZ domains of ZO-2 or
ZO-3 was observed (fig. 3a). The interaction between
the T233R mutant peptide and the ZO-1 PDZ domains
was strongly impaired. Binding to the immobilized wild-
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type CLDN16 peptide was abolished if the in vitro trans-
lated ZO-1 PDZ domains were preincubated with sol-
uble wild-type CLDN16 peptide, whereas the T233R
peptide had no effect (fig. 3b), confirming the specificity
of the interaction. Furthermore, in renal distal tubule
MDCK cells stably expressing wild-type or mutant
CLDN16 carrying an N-terminal hemagglutinin-epitope
tag, wild-type CLDN16, but not the T233R mutant,
coprecipitated with ZO-1 (fig. 3c), consistent with the
in vitro binding data. In conclusion, CLDN16 specifi-
cally binds to ZO-1, and this interaction is abolished by
the T233R mutation.
The T233R Mutation Results in Lysosomal
Mislocalization of CLDN16
In agreement with the TJ localization in kidney cells
in human tissue (Simon et al. 1999), wild-type CLDN16
was present at the height of TJ of transfected polarized
MDCK cell monolayers, in which confocal microscopy
showed that it colocalized with ZO-1 (fig. 4a). In-
triguingly, however, the bulk of the T233R mutant
showed an intracellular vesicular distribution and was
no longer present at the plasma membrane. Vertical con-
focal sections along the apicobasal axis of the cell mono-
layer confirmed the colocalization of CLDN16 and ZO-
1 to the TJ and the mislocalization of the T233R mutant
(fig. 4b). ZO-1 localization was not affected in cells ex-
pressing T233R, a result expected because of the lack
of interaction between the two proteins. Thus, the
T233R mutation affects the association of CLDN16
with ZO-1 as well as its correct TJ targeting. In contrast
to T233R, a previously described CLDN16 mutation
associated with FHNNC, G128A (see fig. 2), was still
correctly targeted to the cell surface, where it colocalized
with ZO-1 at TJ (fig. 4a and 4b). Therefore, at least
some of the FHNNC-linked mutations affecting the
transmembrane or luminal domains of CLDN16 do not
interfere with intracellular transport and/or correct lo-
calization of CLDN16 to TJ.
To determine the nature of the intracellular compart-
ment in which the T223R mutant accumulated, CLDN16
and different organelles were labeled in cells expressing
either wild-type or mutant CLDN16. Mutant, but not
wild-type, CLDN16 extensively colocalized with lamp-2,
a marker for late endosomes and lysosomes (Nabi et
al. 1991; Hunziker and Geuze 1996) (fig. 4c). In con-
trast, no colocalization with the Golgi marker GM130
was observed, a result indicative of normal transport of
T233R in the secretory pathway. Thus, the T233R mu-
tant CLDN16 is mistargeted to lysosomes.
Discussion
Different members of the claudin family are involved in
the establishment of the epithelial TJ barrier, in which
they form paracellular ion channels with distinct sub-
strate selectivity (Heiskala et al. 2001). The crucial role
of claudins in ion homeostasis has been highlighted by
the association of mutations in CLDN14 with deafness
(Wilcox et al. 2001) and CLDN16 with FHHNC (Simon
et al. 1999). Despite minor variations in the clinical phe-
notype in classical FHHNC, patients generally exhibit
renal Mg2 and Ca2 wasting, impaired renal function,
and, in most cases, chronic renal failure at the time of
diagnosis (Weber et al. 2000; Blanchard et al. 2001).
About one-third of patients develop end stage renal dis-
ease in the 1st to 2nd decade of life, resulting in the need
for renal replacement therapy (Weber et al. 2000).
In the patients described in the present article, an
identical and novel mutation in the PDZ-binding motif
of CLDN16 correlated with similar clinical manifesta-
tions that differ in several aspects from the reported
cases of classical FHHNC (Simon et al. 1999; Weber et
al. 2000, 2001b; Blanchard et al. 2001). First, HC was
clearly reduced from childhood to adolescence, return-
ing to normal values in adulthood. NC was either re-
versible or did not progress. Second, hypomagnesemia
was either not encountered (family A) or was only bor-
derline during a single examination (family B), indicat-
ing that, although Mg2 loss was slightly greater than
normal, the loss was small enough to be compensated,
probably by increased uptake via the gut. Third, renal
function, as assessed by glomerular filtration rates, was
unaffected. These clinical differences indicate that these
patients only partially fulfill the criteria of FHHNC.
Thus, if the present results are confirmed by larger co-
hort screenings, mutations affecting the PDZ-binding
motif of CLDN16 may help to define a group of HC-
associated disorders in which self-limiting infantile renal
Ca2 wasting is the most obvious symptom (Alon and
Berenbom 2000; the present study). Mg2 wastage, al-
though consistently different between affected and non-
affected family members, was not of pathological sig-
nificance. No similar cases of self-limiting HC could be
clearly documented in the other nine families in the
cohort that did not present mutations in the CLDN16
gene (Weber et al. 2001b).
The extent of HC in infancy may reflect a higher
turnover of Ca2 in childhood, indicating that CLDN16
may play a more important role in Ca2 metabolism
during growth than during adolescence and adult-
hood. On the other hand, since levels of PTH and
1,25(OH)2D3 increased at the end of a Ca
2-restriction
diet, the reduced renal Ca2 absorption is probably com-
pensated by increased production of PTH and increased
Ca2 resorption from the bone. Thus, physiological
Figure 4 Subcellular localization of wild-type and mutant CLDN16. a, Colocalization of CLDN16 and ZO-1 is abolished by the T233R
mutation. MDCK cells stably expressing wild-type (CLDN16) or mutant (T233R or G128A) CLDN16 grown as polarized cell monolayers on
polycarbonate filters were stained for ZO-1 (red) and CLDN16 (green), and confocal images corresponding to horizontal sections at the height
of TJ were acquired. The merged image shows regions where CLDN16 and ZO-1 colocalize (yellow). b, TJ localization of CLDN16 is abolished
by the T233R mutation. Vertical confocal sections along the apico-basal axis of the cell monolayers expressing wild-type (CLDN16) or mutant
(T233R or G128A) CLDN16 labeled for CLDN16 (green) or ZO-1 (red). The positions of the filter supporting the cells and the TJ are indicated.
c, T233R localized to lysosomes. MDCK cells transfected with wild-type (CLDN16) or mutant (T233R) CLDN16 were stained to visualize
lysosomes (anti–lamp-2) or the Golgi complex (anti-GM130) (red) and CLDN16 (green), and confocal images were acquired. The T223R
mutant shows extensive localization to lyososmes (merged image; yellow), but not the Golgi complex.
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bone mass loss in senescence might deteriorate by ad-
ditional renal Ca2 loss, and the patients carrying the
T233R mutant may be at a higher risk for osteoporosis
later in life, when renal Ca2 conservation mechanisms
are required. This particular importance of CLDN16 in
Ca2-homeostasis is supported by the high incidence of
calcium-related kidney stone disease in individuals car-
rying heterozygous CLDN16 mutations (Weber et al.
2001b), although we did not observe HC or kidney
stones in the heterozygous family members of our pa-
tients. The fact that desmopressin relieved nocturnal
enuresis in all affected patients contradicts the hypoth-
esis of a close correlation of urinary Ca2 excretion and
nocturnal enuresis (Alon et al. 1990; Valenti et al.
2000), indicating that its therapeutic benefit in this dis-
order may rather be due to a nonrenal effect (Muller et
al. 2002b).
The CLDN16 mutations reported so far are all as-
sociated with classical FHHNC and located within the
extracellular loops or the transmembrane domains of
the molecule (Simon et al. 1999; Weber et al. 2000;
Blanchard et al. 2001; Weber et al. 2001b) (fig. 2). To
date, there are no functional expression studies of either
wild-type or mutant CLDN16, but it was hypothesized
that mutations in the extracellular loops alter the charge
selectivity in the pore-forming region of the protein,
hence interfering with the diffusion of divalent ions. The
present study characterizes the mutation that, to our
knowledge, is the first to be described in the C-terminal
cytosolic tail of CLDN16 and the first to affect the PDZ-
binding motif. Inactivation of the PDZ-binding motif
in T233R abolishes the interaction of CLDN16 with
the PDZ domains of the scaffolding protein ZO-1, one
of whose functions is to link transmembrane TJ proteins
to the actin cytoskeleton (Gonzalez-Mariscal et al. 2000).
It is interesting that, instead of localizing to the TJ,
the T233R mutant is misdirected to lysosomes. Thus,
ZO-1 may tether CLDN16 to the TJ and prevent its
internalization and subsequent lysosomal delivery.
Because the T233R substitution does not create a
known type of lysosomal sorting signal (Hunziker and
Geuze 1996), several putative endocytosis and/or ly-
sosomal sorting determinants present in the cytosolic
domain of CLDN16 (fig. 2) may be responsible for ly-
sosomal targeting once tethering to ZO-1 is disrupted.
The detection of low amounts of T233R at the plasma
membrane indeed suggests that T233R may be delivered
to the TJ but not be retained there. Thus, the mutation
may not affect the formation of a functional paracellular
ion channel per se but rather shorten the residence
time of CLDN16 at the TJ, thus reducing the number
of CLDN16 molecules present at the TJ at any given
time. Such a molecular mechanism—possibly combined
with higher CLDN16 expression levels in adults and a
general decrease, which occurs as individuals mature,
in body weight and body surface that is related to Ca2
excretion (Kruse et al. 1984)—may provide an expla-
nation for the mild phenotype of FHHNC observed in
the patients described here. Lysosomal mistargeting pro-
vides—for the first time, to our knowledge—insight into
a molecular mechanism for a CLDN16 mutation as-
sociated with a clinical phenotype. Furthermore, be-
cause a mutant with an intact PDZ-binding motif but
a single amino acid substitution in the luminal/trans-
membrane domain (G128A) correctly localizes to TJ, it
is likely that, depending on the particular mutation in
CLDN16, different molecular mechanisms can lead to
FHHNC.
In conclusion, the T233R mutant will be useful to
further dissect the role of the interaction with ZO pro-
teins in TJ localization, intracellular transport, and turn-
over of CLDN16. The mutation may also provide a
differential diagnostic and prognostic tool for a less se-
vere form of FHHNC, with self-limiting childhood HC
being the leading symptom.
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